Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak et al. · New England Journal of Medicine · 2001 · 11.4K citations · Full text

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Brian D. Lehmann, Joshua A. Bauer, Xi Chen et al. · Journal of Clinical Investigation · 2011 · 5.3K citations · Full text

Androgen Receptor, Breast Oncology, Tumor Biology +16

Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience

Andrew D. Seidman, Clifford A. Hudis, Mary Kathryn Pierri et al. · Journal of Clinical Oncology · 2002 · 1.5K citations

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

Jagath R. Junutula, Helga Raab, Suzanna Clark et al. · Nature Biotechnology · 2008 · 1.3K citations

Medicinal Chemistry, Immunocytochemical Technique, Drug Targeting +10

Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival

Adedayo A. Onitilo, Jessica M. Engel, Robert T. Greenlee et al. · Clinical Medicine & Research · 2009 · 765 citations

Immunohematology, Breast Oncology, Immunology +24